Brief: Inventiva Announces Positive Recommendation Phase III Clinical Trial With Lanifibranor In Patients With Nash
04/12/2023 21:35
Dec 5 (Reuters) - Inventiva SA IVAA.PA :
* INVENTIVA ANNOUNCES THE POSITIVE RECOMMENDATION OF THE
THIRD DMC
OF THE PHASE III CLINICAL TRIAL WITH LANIFIBRANOR IN PATIENTS
WITH NASH
* INVENTIVA SA: DMC REVIEW REMAINS CONSISTENT, CONFIRMING
GOOD
SAFETY PROFILE OF LANIFIBRANOR
* INVENTIVA SA: DMC RECOMMENDED TO CONTINUE CLINICAL TRIAL
WITHOUT
MODIFICATION OF PROTOCOL, BASED ON PRE-PLANNED REVIEW OF SAFETY
DATA
Source text for Eikon: ID:nGNX4DYbpd
Further company coverage: IVAA.PA
((Reuters.Briefs@thomsonreuters.com))
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030